Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B.

Slides:

Advertisements

Similar presentations

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Advertisements

Feedback loop (CV changes input) SP Controller Gc Plant Gp Sensor Gs E MV (Manipulated Variable CV Controlled Variable +-+- S.

Supplementary Figure 1 Select oncogenic target of interest Choose an oncogene-driven cell line and a cell line to be used as a counterscreen OCI-AML3 Ba/F3-NRAS-G12D.

Supplemental Figure 1 A No. at risk T T T

CD68 NE-SSE NE-NS Figure E1. Nrf2 42-kD  actin 32-kD HO kD Control si RNA si RNA Nrf2 Control si RNA si RNA Nrf2 Control si RNA si RNA Nrf2 Control.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

People Fractions. Problem 1 of 20 Answer 1 = 10 Problem 2 of 20 Answer 2 = 5.

Serum dilution OD 405 nm PNAG CP5 CP8 AB C Supplemental Figure 1: ELISA analysis of IgG antibody binding in the pre-immune sera of the 9 groups of mice.

Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.

Herceptin + 17-AAG Combination BT-474 Tumors

Supplemental Figure 1 A B panobinostat.

Supplemental Figure 1 Auranofin BSO Zn-BG ABC D carfilzomib.

The exponent is most often used in the power of monomials.

Unexpected additional thyroid cancer in a patient with already known cervical cancer detected on PET/CT Kaohsiung Veterans General Hospital Kuan-Hsiu Lin,

Fractions and Decimal Fractions Fractions Decimal Fractions

Practice using fractions, decimals, and percents with place value, number lines, shaded shapes, and shaded 10 x 10 grids.

親愛的吉姆舅舅：今天吃完晚餐後，奶奶說，在家裡情況變好以前，您要我搬到城裡跟您住。奶奶有沒有跟您說，爸爸已經好久沒有工作，也好久沒有人請媽媽做衣服了？我們聽完都哭了，連爸爸也哭了，但是媽媽說了一個故事讓我們又笑了。她說：您們小的時候，她曾經被您追得爬到樹上去，真的嗎？雖然我個子小，但是我很強壯，

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

1.4 Sketching Intersections

Copyright © 2013 American Medical Association. All rights reserved.

500 mg total protein /mL S-CM 250 mg total protein /mL S-CM

EPP Peak #1 Extraction 1 Extraction 2 Extraction 3 Gel 1 Gel 2

Volume 30, Issue 4, Pages (October 2016)

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against.

Supplemental Figures Supplemental Figure 1.

A B C Supplemental Figure S1 SET2 HEL BRD4 β-Actin SET2

Supplementary Figure 1 Oligomycin, 1µM FCCP,

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts.

Supplemental Figure S1 B A C D.

Supplemental Figure 1 Li Fraumeni (087) 5C tankyrase1 actin Mock

Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications–Positive Acute.

Supplemental Tables/Figures

Supplemental figure 1B Indicated cell lines were incubated with venetoclax (VEN) in combination with ara-C or idarubicin (IDA), for 48h and viability assessed.

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,

Supplemental Figure 1A – I

Volume 93, Issue 1, Pages (January 2017)

500 nm WRITE VOLTAGE 0 V.

Supplemental Figure 1 1 mutation 2 mutations 3 mutations 4 mutations

Peptide ID# Pulsed to T2-A24 Cells

Reasoning with Operations with Fractions

CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

Supplemental Figure 1 Patient 2.

Reh cells, 24 hours c-Myc Ac-p53 b-actin

Methods applied in addition

Volume 15, Issue 4, Pages (October 2014)

Supplemental Figure 4 A no agonist MALP2 PAM3CSK4 GFP WT F217S

Volume 30, Issue 4, Pages (October 2016)

Supplemental Figure 1A SMM Patient #1 MP-CTL % CD3+ CD8+ T Cells

PRC2 and HOTAIR in vitro production

Vehicle Akti 0’ 2’ 5’ 10’ 0’ 2’ 5’ 10’ AktT308 β-actin GSK3βS9 β-actin

Induction of apoptosis by nelfinavir and bortezomib

by Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E

Powers and indices: Fractional Indices

LSD1, a histone demethylase, is required for the assembly of the Notch repressor complex. LSD1, a histone demethylase, is required for the assembly of.

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Supplemental Figure S1 A B Adults Neonates Adult CD103+ DC: KdM282-90

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Volume 84, Issue 6, Pages (June 2003)

A B Supplemental Figure S1 OCI-AML-3 (FLT3 WT) MOLM-13 (FLT3 ITD)

Treatment with DZNep depletes expression of PRC2 proteins EZH2, SUZ12, and associated 3MeK27H3 levels in cultured human MCL cells. Treatment with DZNep.

Activation of Vγ9 T cells by three distinct stimuli is CD277 dependent

SY-1425 induces maturation in RARA-high AML

Figure 1 B A C D Pomc 151 bp M Sp pc nc 362 bp Actb Sp Kidney

e a b c d unstimulated +fMLP T308P-Akt S473P-Akt Akt (min)

Li and Xue, Supplemental Figure 1

Supplementary Table 1. TTI-621 binds to human tumor cell lines

Presentation transcript:

Supplemental Figure 1

Supplemental Figure 2

Supplemental Figure 3 A B

OCI-AML3 IgG ControlControl nM SP2509, 24 h CD86 MOLM13 CD86 Supplemental Figure 4 A B

MV4-11 SP PS combination indices SP2509PSFaCI(nM) MV4-11 SP PS Fractional Effect CI C Supplemental Figure 5 OCI-AML3 SP PS combination indices SP2509PSFaCI(nM) MOLM13 SP PS combination indices SP2509PSFaCI(nM) A B Primary CD34+ CD38- Lin- AML combination indices SP2509 (nM) PS (nM) FaCI D

B * OCI-AML3 p21 p16 EZH2 C/EBPα p42 C/EBPα p30 LSD1 SUZ12 β-Actin 250 nM SP2509, 96 h 5 nM PS, 96 h A Supplemental Figure 6

Supplemental Figure 7 Primary AML SP2509 and PS SP2509 (nM) PS (nM) EffectCI A B